8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Day One Biopharmaceuticals, Inc.(DAWN)Earnings, Financials & Key Ratios
DAWN•NASDAQ
$21.53
$2.22B mkt cap·Price updated May 6, 2026
AboutDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$158M+20.6%
- EBITDA-$124M+42.3%
- Net Income-$107M-12.4%
- EPS (Diluted)-1.04-2.0%
- Gross Margin89.12%-7.1%
- EBITDA Margin-78.56%+52.1%
- Operating Margin-80.76%+51.2%
- Net Margin-67.85%+6.8%
- ROE-22.74%-1.1%
- ROIC-30.55%+53.5%
- Debt/Equity0.01+22.3%
DAWN Key Insights
Day One Biopharmaceuticals, Inc. (DAWN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 21.5% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 10.4% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DAWN Price & Volume
Day One Biopharmaceuticals, Inc. (DAWN) stock price & volume — 10-year historical chart
Loading chart...
DAWN Growth Metrics
Day One Biopharmaceuticals, Inc. (DAWN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM20.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4.64%
Return on Capital
10 Years-47.1%
5 Years-46.17%
3 Years-46.06%
Last Year-26.71%
DAWN Recent Earnings
Day One Biopharmaceuticals, Inc. (DAWN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (57%)
Q1 2026Latest
Feb 24, 2026EPS
$0.20
Est $0.17
-17.6%
Revenue
$54M
Est $50M
+7.7%
Q4 2025
Nov 4, 2025EPS
$0.19
Est $0.28
+31.8%
Revenue
$40M
Est $38M
+4.2%
Q3 2025
Aug 5, 2025EPS
$0.29
Est $0.35
+17.1%
Revenue
$34M
Est $40M
-14.4%
Q2 2025
May 6, 2025EPS
$0.35
Est $0.46
+23.9%
Revenue
$31M
Est $37M
-15.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.20vs $0.17-17.6% | $54Mvs $50M+7.7% |
| Q4 2025 | Nov 4, 2025 | $0.19vs $0.28+31.8% | $40Mvs $38M+4.2% |
| Q3 2025 | Aug 5, 2025 | $0.29vs $0.35+17.1% | $34Mvs $40M-14.4% |
| Q2 2025 | May 6, 2025 | $0.35vs $0.46+23.9% | $31Mvs $37M-15.8% |
Based on last 12 quarters of dataView full earnings history →
DAWN Peer Comparison
Day One Biopharmaceuticals, Inc. (DAWN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KURA | 816.17M | 9.29 | -2.92 | 25.24% | -412.95% | -102.59% | 0.06 | |
 TGTX | 5.7B | 36.10 | 240.67 | 40.8% | 13.31% | 21.87% | 1.14 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ERAS | 2.83B | 9.99 | -14.48 | -36.7% | 0.12 |
Compare DAWN vs Peers
Day One Biopharmaceuticals, Inc. (DAWN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DAWN Income Statement
Day One Biopharmaceuticals, Inc. (DAWN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 131.16M | 158.18M |
| Revenue Growth % | - | - | - | - | - | - | 20.6% |
| Cost of Goods Sold | 0 | 155K | 199K | 531K | 383K | 5.28M | 17.21M |
| COGS % of Revenue | - | - | - | - | - | 4.02% | 10.88% |
| Gross Profit | 0▲ 0% | -155K▲ 0% | -199K▼ 28.4% | -531K▼ 166.8% | -383K▲ 27.9% | 125.88M▲ 32967.4% | 140.97M▲ 12.0% |
| Gross Margin % | - | - | - | - | - | 95.98% | 89.12% |
| Gross Profit Growth % | - | - | -28.39% | -166.83% | 27.87% | 32967.36% | 11.99% |
| Operating Expenses | 14.9M | 13.63M | 72.54M | 146.38M | 205.68M | 343.15M | 268.72M |
| OpEx % of Revenue | - | - | - | - | - | 261.63% | 169.88% |
| Selling, General & Admin | 1.01M | 4.53M | 28.96M | 60.76M | 75.16M | 115.45M | 120.59M |
| SG&A % of Revenue | - | - | - | - | - | 88.02% | 76.23% |
| Research & Development | 13.9M | 9.1M | 43.58M | 85.62M | 130.52M | 227.7M | 148.13M |
| R&D % of Revenue | - | - | - | - | - | 173.61% | 93.65% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.9M▲ 0% | -13.78M▲ 7.5% | -72.74M▼ 427.8% | -146.91M▼ 102.0% | -206.06M▼ 40.3% | -217.27M▼ 5.4% | -127.75M▲ 41.2% |
| Operating Margin % | - | - | - | - | - | -165.65% | -80.76% |
| Operating Income Growth % | - | 7.53% | -427.81% | -101.96% | -40.27% | -5.44% | 41.2% |
| EBITDA | 0 | -13.63M | -72.54M | -146.38M | -205.68M | -215.24M | -124.27M |
| EBITDA Margin % | - | - | - | - | - | -164.1% | -78.56% |
| EBITDA Growth % | - | - | -432.35% | -101.78% | -40.51% | -4.65% | 42.26% |
| D&A (Non-Cash Add-back) | 14.9M | 155K | 199K | 531K | 383K | 2.03M | 3.48M |
| EBIT | -14.91M | -43.81M | -72.75M | -142.18M | -188.92M | -88.35M | -109.3M |
| Net Interest Income | -2.08M | -30K | 4K | 4.75M | 17.19M | 19.7M | 18.47M |
| Interest Income | 0 | 0 | 4K | 4.75M | 17.19M | 19.7M | 18.47M |
| Interest Expense | 2.08M | 30K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.08M | -30.06M | -11K | 4.73M | 17.15M | 128.92M | 18.45M |
| Pretax Income | -16.98M▲ 0% | -43.84M▼ 158.1% | -72.75M▼ 65.9% | -142.18M▼ 95.4% | -188.92M▼ 32.9% | -88.35M▲ 53.2% | -109.3M▼ 23.7% |
| Pretax Margin % | - | - | - | - | - | -67.36% | -69.1% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 7.14M | -1.98M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -8.09% | 1.81% |
| Net Income | -12.63M▲ 0% | -40.51M▼ 220.6% | -70.64M▼ 74.4% | -142.18M▼ 101.3% | -188.92M▼ 32.9% | -95.5M▲ 49.5% | -107.32M▼ 12.4% |
| Net Margin % | - | - | - | - | - | -72.81% | -67.85% |
| Net Income Growth % | - | -220.62% | -74.4% | -101.26% | -32.87% | 49.45% | -12.38% |
| Net Income (Continuing) | -16.98M | -43.84M | -72.75M | -142.18M | -188.92M | -95.5M | -107.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 5.49M | 5.7M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24▲ 0% | -0.65▼ 170.8% | -1.14▼ 75.4% | -2.02▼ 77.2% | -2.37▼ 17.3% | -1.02▲ 57.0% | -1.04▼ 2.0% |
| EPS Growth % | - | -170.83% | -75.38% | -77.19% | -17.33% | 56.96% | -1.96% |
| EPS (Basic) | -0.24 | -0.65 | -1.14 | -2.02 | -2.37 | -1.02 | -1.04 |
| Diluted Shares Outstanding | 61.93M | 61.93M | 61.95M | 65.47M | 79.77M | 93.62M | 103.38M |
| Basic Shares Outstanding | 61.93M | 61.93M | 61.95M | 65.47M | 79.77M | 93.62M | 103.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
DAWN Balance Sheet
Day One Biopharmaceuticals, Inc. (DAWN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 27.34M | 45.07M | 289.37M | 347.87M | 375.27M | 562.33M | 485.1M |
| Cash & Short-Term Investments | 27.33M | 43.73M | 284.31M | 342.27M | 366.35M | 531.72M | 441.11M |
| Cash Only | 27.33M | 43.73M | 284.31M | 85.26M | 230.78M | 124.97M | 197.08M |
| Short-Term Investments | 0 | 0 | 0 | 257.01M | 135.56M | 406.75M | 244.03M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 13.88M | 26.73M |
| Days Sales Outstanding | - | - | - | - | - | 38.61 | 61.69 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.32M | 6.33M |
| Days Inventory Outstanding | - | - | - | - | - | 229.62 | 134.17 |
| Other Current Assets | 0 | 1.26M | 1.01M | 1.01M | 2.35M | 4.37M | 10.93M |
| Total Non-Current Assets | 0 | 590K | 453K | 1.19M | 774K | 20.46M | 22.73M |
| Property, Plant & Equipment | 0 | 483K | 284K | 719K | 560K | 4.71M | 4.48M |
| Fixed Asset Turnover | - | - | - | - | - | 27.87x | 35.32x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 15.63M | 18.02M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 107K | 169K | 469K | 214K | 121K | 230K |
| Total Assets | 27.34M▲ 0% | 45.66M▲ 67.0% | 289.82M▲ 534.7% | 349.06M▲ 20.4% | 376.05M▲ 7.7% | 582.79M▲ 55.0% | 507.83M▼ 12.9% |
| Asset Turnover | - | - | - | - | - | 0.23x | 0.31x |
| Asset Growth % | - | 67.02% | 534.72% | 20.44% | 7.73% | 54.98% | -12.86% |
| Total Current Liabilities | 2.02M | 2M | 8.66M | 16.61M | 29.51M | 73.45M | 60.52M |
| Accounts Payable | 69K | 202K | 1.74M | 260K | 2.58M | 3.26M | 3.73M |
| Days Payables Outstanding | - | 475.68 | 3.2K | 178.72 | 2.45K | 225.54 | 79.17 |
| Short-Term Debt | 0 | 0 | 204K | 405K | 408K | 10K | 174K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1.55M | 2M |
| Other Current Liabilities | 1.49M | 27K | 104K | 9.82M | 17.36M | 54.68M | 54.62M |
| Current Ratio | 13.53x | 22.58x | 33.43x | 20.94x | 12.72x | 7.66x | 8.02x |
| Quick Ratio | 13.53x | 22.58x | 33.43x | 20.94x | 12.72x | 7.61x | 7.91x |
| Cash Conversion Cycle | - | - | - | - | - | 42.69 | 116.68 |
| Total Non-Current Liabilities | 30.5M | 204K | 16K | 408K | 0 | 6.59M | 6.14M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.62M |
| Capital Lease Obligations | 0 | 204K | 16K | 408K | 0 | 2.59M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 30.5M | 0 | 0 | 0 | 0 | 761K | 3.52M |
| Total Liabilities | 32.52M | 2.2M | 8.67M | 17.02M | 29.51M | 80.04M | 66.67M |
| Total Debt | 0 | 402K | 220K | 813K | 408K | 2.6M | 2.79M |
| Net Debt | -27.33M | -43.33M | -284.09M | -84.45M | -230.38M | -122.37M | -194.28M |
| Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -7.18x | -1460.43x | - | - | - | - | - |
| Total Equity | -5.19M▲ 0% | 43.46M▲ 938.0% | 281.15M▲ 546.9% | 332.04M▲ 18.1% | 346.54M▲ 4.4% | 502.75M▲ 45.1% | 441.16M▼ 12.3% |
| Equity Growth % | - | 938.04% | 546.9% | 18.1% | 4.37% | 45.08% | -12.25% |
| Book Value per Share | -0.08 | 0.70 | 4.54 | 5.07 | 4.34 | 5.37 | 4.27 |
| Total Shareholders' Equity | -10.67M | 37.76M | 281.15M | 332.04M | 346.54M | 502.75M | 441.16M |
| Common Stock | 2M | 2.64M | 6K | 7K | 9K | 10K | 10K |
| Retained Earnings | -12.78M | -56.84M | -127.49M | -269.67M | -458.58M | -554.08M | -661.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 111 | 0 | 0 | -71K | 9K | 84K | 65K |
| Minority Interest | 5.49M | 5.7M | 0 | 0 | 0 | 0 | 0 |
DAWN Cash Flow Statement
Day One Biopharmaceuticals, Inc. (DAWN) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.51M | -13.49M | -48.54M | -109.87M | -146.85M | -78.11M | -103.76M |
| Operating CF Margin % | - | - | - | - | - | -59.56% | -65.59% |
| Operating CF Growth % | - | -198.76% | -259.84% | -126.36% | -33.66% | 46.81% | -32.83% |
| Net Income | -16.98M | -43.84M | -72.75M | -142.18M | -188.92M | -95.5M | -107.32M |
| Depreciation & Amortization | 0 | 155K | 199K | 531K | 383K | 2.03M | 3.48M |
| Stock-Based Compensation | 111K | 526K | 13.32M | 27.24M | 39.34M | 48.26M | 44.39M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.91M | 30.03M | 8M | -2.03M | -7.08M | -59.39M | -15.36M |
| Working Capital Changes | 444K | -357K | 2.69M | 6.56M | 9.42M | 26.48M | -28.94M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -13.88M | -12.86M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.24M | -2.86M |
| Change in Payables | 14K | 132K | 1.54M | -1.48M | 2.32M | 686K | 471K |
| Cash from Investing | 0 | -92K | -8M | -255.07M | 128.38M | -230.99M | 174.65M |
| Capital Expenditures | 0 | -92K | -8M | -26K | -224K | -2.17M | -320K |
| CapEx % of Revenue | - | - | - | - | - | 1.65% | 0.2% |
| Acquisitions | 0 | 0 | 0 | 255.05K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -255.05K | -3M | 35.9M | -3.47M |
| Cash from Financing | 30.91M | 29.98M | 297.12M | 165.9M | 164M | 203.29M | 1.22M |
| Debt Issued (Net) | 1M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 29.91M | 29.98M | 296.8M | 161.61M | 164M | 178.18M | 1.22M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 318K | 4.29M | 0 | 25.11M | 0 |
| Net Change in Cash | 26.39M▲ 0% | 16.4M▼ 37.9% | 240.58M▲ 1367.3% | -199.05M▼ 182.7% | 145.52M▲ 173.1% | -105.82M▼ 172.7% | 72.11M▲ 168.1% |
| Free Cash Flow | -4.51M▲ 0% | -13.58M▼ 200.8% | -56.54M▼ 316.3% | -109.9M▼ 94.4% | -150.08M▼ 36.6% | -80.28M▲ 46.5% | -104.08M▼ 29.6% |
| FCF Margin % | - | - | - | - | - | -61.21% | -65.8% |
| FCF Growth % | - | -200.8% | -316.31% | -94.38% | -36.56% | 46.51% | -29.64% |
| FCF per Share | -0.07 | -0.22 | -0.91 | -1.68 | -1.88 | -0.86 | -1.01 |
| FCF Conversion (FCF/Net Income) | 0.36x | 0.33x | 0.69x | 0.77x | 0.78x | 0.82x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 1.9M | 0 |
DAWN Key Ratios
Day One Biopharmaceuticals, Inc. (DAWN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -211.66% | -43.53% | -46.37% | -55.68% | -22.49% | -22.74% |
| Return on Invested Capital (ROIC) | - | - | - | -90.07% | -84.97% | -65.63% | -30.55% |
| Gross Margin | - | - | - | - | - | 95.98% | 89.12% |
| Net Margin | - | - | - | - | - | -72.81% | -67.85% |
| Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
| Interest Coverage | -7.18x | -1460.43x | - | - | - | - | - |
| FCF Conversion | 0.36x | 0.33x | 0.69x | 0.77x | 0.78x | 0.82x | 0.97x |
| Revenue Growth | - | - | - | - | - | - | 20.6% |
DAWN SEC Filings & Documents
Day One Biopharmaceuticals, Inc. (DAWN) SEC filings — annual & quarterly reports (10-K, 10-Q)
DAWN Frequently Asked Questions
Day One Biopharmaceuticals, Inc. (DAWN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in revenue for fiscal year 2025.
Day One Biopharmaceuticals, Inc. (DAWN) grew revenue by 20.6% over the past year. This is strong growth.
Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $107.3M for fiscal year 2025.
Dividend & Returns
Day One Biopharmaceuticals, Inc. (DAWN) has a return on equity (ROE) of -22.7%. Negative ROE indicates the company is unprofitable.
Day One Biopharmaceuticals, Inc. (DAWN) had negative free cash flow of $107.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More DAWN
Day One Biopharmaceuticals, Inc. (DAWN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates